$3.07
0.97% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US74365U1079
Symbol
TARA

Protara Therapeutics Inc Stock price

$3.07
-0.09 2.85% 1M
-1.08 26.02% 6M
-2.21 41.86% YTD
+1.13 58.25% 1Y
-0.44 12.54% 3Y
-22.34 87.92% 5Y
-576.53 99.47% 10Y
-398.13 99.23% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.03 0.97%
ISIN
US74365U1079
Symbol
TARA
Industry

Key metrics

Basic
Market capitalization
$119.6m
Enterprise Value
$-4.8m
Net debt
positive
Cash
$124.4m
Shares outstanding
38.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.1
P/B
0.8
Financial Health
Equity Ratio
92.1%
Return on Equity
-26.9%
ROCE
-32.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-50.2m | -
EBIT
$-51.8m | $-60.6m
Net Income
$-45.4m | $-55.1m
Free Cash Flow
$-40.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-10.1% | -
EBIT
-12.8% | -23.7%
Net Income
-7.2% | -22.4%
Free Cash Flow
-17.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.1
FCF per Share
$-1.1
Short interest
7.7%
Employees
31
Rev per Employee
$0.0
Show more

Is Protara Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Protara Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Protara Therapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Protara Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Protara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
1% 1%
-
- Research and Development Expense 33 33
20% 20%
-
-50 -50
10% 10%
-
- Depreciation and Amortization 1.61 1.61
374% 374%
-
EBIT (Operating Income) EBIT -52 -52
13% 13%
-
Net Profit -45 -45
7% 7%
-

In millions USD.

Don't miss a Thing! We will send you all news about Protara Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protara Therapeutics Inc Stock News

Neutral
GlobeNewsWire
one day ago
Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support on track for 3Q 2025   On track to provide an interim update from the Phase 2 STARBORN-1 trial o...
Neutral
GlobeNewsWire
11 days ago
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees.
Neutral
GlobeNewsWire
about one month ago
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees.
More Protara Therapeutics Inc News

Company Profile

Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.

Head office United States
CEO Jesse Shefferman
Employees 31
Founded 2006
Website protaratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today